A new study shows how a blood sample could help doctors track an aggressive form of lung cancer and understand its biology, bringing more personalized treatment a step closer.

For someone with small-cell lung cancer, treatment can begin with a frustrating pattern: the tumor shrinks, then returns. When it does, doctors need to understand what has changed. But getting another sample of the cancer can require an invasive biopsy—and for small-cell lung cancer patients, that is difficult and can hasten disease progression.

Now, researchers have shown that some of those answers may be found in a blood sample.

An international team led by Prof. Nir Friedman and Dr. Gavriel Fialkoff of the Hebrew University-Hadassah Medical School, alongside Dr. Nobuyuki Takahashi and Dr. Anish Thomas of the US National Cancer Institute, part of the National Institutes of Health (NIH), developed a blood-based approach that could help reveal how much cancer is present and which biological programs are active inside it.

Published in the Journal of Clinical Investigation, the study offers a promising route toward monitoring a fast-moving disease without repeatedly collecting tumor tissue.

Small-cell lung cancer accounts for approximately 15% of lung cancer cases. It often grows and spreads quickly, and many patients are diagnosed after the disease has reached an advanced stage.

Despite its name, it is not one uniform disease. Tumors that look similar under a microscope use different sets of active genes. Those differences may help explain how a tumor behaves and which treatments might work against it.

The challenge is finding that information and keeping it up to date as the cancer changes.

The researchers turned to tiny fragments of material that dying cells release into the bloodstream. These include pieces of DNA wrapped around proteins called histones. Chemical marks on those proteins provide clues about which genes were active in the cells they came from.

Using a technique called cfChIP-seq, the team examined these signals to learn about the cancer cells that released them. While many existing liquid biopsies search for changes in DNA’s genetic code, this approach looks for evidence of how cells are using that code.

The researchers analyzed 441 blood plasma samples from people with small-cell lung cancer, people with other cancers, and healthy individuals. They also compared blood findings with gene activity measured in tumor samples.

The technique required only about one milliliter of plasma, the liquid part of blood.

The team identified molecular patterns characteristic of small-cell lung cancer and developed a quantitative measure of the strength of those cancer-associated signals.

The blood-based measure correlated with the amount of cancer measured by medical imaging and changed during treatment. Across the patients studied, the median score fell after treatment, consistent with reduced tumor mass. Higher scores were also associated with shorter survival in the study group.

Together, these findings suggest that the approach could eventually give doctors another way to assess how the disease is progressing and responding to therapy.

The blood samples also revealed clues about different molecular subtypes of small-cell lung cancer. Signals detected in the blood of a patient closely reflected the activity of key genes in tumor tissue of the same patient.

That matters because emerging treatments may work differently against different subtypes. An accessible way to identify those differences could help doctors match patients with suitable therapies as those treatments develop.

Some samples carried signals linked to more than one subtype, highlighting the disease’s complexity. Because blood can collect material released by cancer cells in different locations, the approach may also offer a broader view than a biopsy taken from a single site.

The method is not yet ready to replace tissue biopsies or guide routine treatment decisions. Larger studies are needed to establish how reliably it tracks changes and whether using its results to choose treatments improves patient outcomes.

For now, the study demonstrates that the bloodstream carries more than evidence that a tumor exists. It can also carry clues about what that tumor is doing. This information could eventually help doctors respond as the cancer changes.